H. Ralph Snodgrass is PRES./CHIEF SCIENTIFIC OFFICER of VistaGen Therapeutics, Inc.. Currently has a direct ownership of 64,958 shares of VTGN, which is worth approximately $213,711. The most recent transaction as insider was on Dec 31, 2021, when has been sold 3,623 shares (Common Stock) at a price of $1.66 per share, resulting in proceeds of $6,014. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 65K
0% 3M change
0% 12M change
Total Value Held $213,711

H. RALPH SNODGRASS Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 31 2021
BUY
Grant, award, or other acquisition
$6,014 $1.66 p/Share
3,623 Added 5.28%
64,958 Common Stock
Sep 02 2021
BUY
Bona fide gift
-
1,111 Added 1.78%
61,335 Common Stock
Jun 30 2021
BUY
Grant, award, or other acquisition
$6,612 $1.95 p/Share
3,391 Added 3.59%
91,115 Common Stock
Dec 31 2020
BUY
Grant, award, or other acquisition
$2,250 $0.45 p/Share
5,000 Added 5.39%
87,724 Common Stock
HRS

H. Ralph Snodgrass

PRES./CHIEF SCIENTIFIC OFFICER
South San Francisco, CA

Track Institutional and Insider Activities on VTGN

Follow VistaGen Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VTGN shares.

Notify only if

Insider Trading

Get notified when an Vista Gen Therapeutics, Inc. insider buys or sells VTGN shares.

Notify only if

News

Receive news related to VistaGen Therapeutics, Inc.

Track Activities on VTGN